On July 23, GENSCRIPT BIO rose 5.38% in regular trading, trading at HK$16.44/share, with turnover of HK$231 million. The move represents a continuation of the technical recovery from the July 17 low of HK$13.12.

On the news front, the company's associate Legend Biotech previously disclosed that CARVYKTI generated net trade sales of approximately $657 million in Q2, representing nearly 50% year-over-year growth and roughly 10% sequential growth from Q1's $597 million. Prior profit-taking pressure triggered by the slower quarter-over-quarter growth rate was largely absorbed last week, and the market has since refocused on the product's strong year-over-year expansion trajectory.

Within the Life Sciences Tools & Services sector, INSILICO rose 5.77%, WUXI APPTEC rose 2.36%, JOINN rose 2.0%, WUXI BIO rose 1.85%, and XTALPI rose 1.14%.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)